Syros Pharmaceuticals’ SYRS shares plunged 61.7% on Aug 13, after the company discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of its investigational candidate, tamibarotene...
Source LinkSyros Pharmaceuticals’ SYRS shares plunged 61.7% on Aug 13, after the company discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of its investigational candidate, tamibarotene...
Source Link
Comments